ICD-10 F13 Codes: Benzodiazepine & Sedative

Category F13 — sedative, hypnotic, or anxiolytic related disorders — is where benzodiazepine diagnoses live, and it carries the highest clinical stakes of any substance family except alcohol: sedative withdrawal can be medically dangerous, which makes withdrawal-code accuracy and detox medical-necessity documentation matter more here than anywhere else. It is also the family with the trickiest boundary question — millions of patients take benzodiazepines exactly as prescribed, and prescribed use is not a use disorder. This guide covers every billable F13 code in the FY2026 set, the prescribed-use boundary, and the billing logic for sedative detox.

All codes and titles are verified against the FY2026 ICD-10-CM code set (effective October 1, 2025) from CDC/NCHS ↗ and CMS ↗; rules cite the ICD-10-CM Official Guidelines FY2026 ↗, Section I.C.5.b. Part of the ICD-10 behavioral health directory.

F13 at a glance

What counts as a “sedative, hypnotic, or anxiolytic”? Three drug groups, in practice:

Searchers and charts say “benzo”; the code set says “sedative, hypnotic or anxiolytic.” Same family, three stems:

The FY2026 inclusion terms carry the DSM-5-TR severity bridge: mild sedative use disorder → F13.10; moderate/severe → F13.20; in remission, mild → F13.11 and moderate/severe → F13.21.

• Benzodiazepines — alprazolam (Xanax), clonazepam (Klonopin), diazepam (Valium), lorazepam (Ativan): the overwhelming majority of F13 diagnoses
• Z-drugs — zolpidem (Ambien), eszopiclone (Lunesta), zaleplon: hypnotics
• Barbiturates and similar agents — phenobarbital, butalbital-containing products

Complete F13 code table (FY2026)

All codes below are valid, billable FY2026 codes. Full official titles spell out “sedative, hypnotic or anxiolytic” in every entry; they’re abbreviated to “SHA” in the table for readability — the code, not the shorthand, goes on the claim. Structure notes versus siblings: intoxication has no perceptual-disturbance 6th character, withdrawal has the full delirium/perceptual-disturbance split (like alcohol), and persisting amnestic disorder and dementia codes exist only under dependence and unspecified use — not abuse.

F13.1- — Abuse

F13.2- — Dependence

F13.9- — Use, unspecified

Prescribed benzodiazepines vs F13 diagnoses

The boundary no competitor code page handles: most people taking benzodiazepines are taking them as prescribed. Three distinct coding situations:

The middle row is where iatrogenic dependence lives, and it is a documentation problem before it is a coding problem: a patient who develops physiologic dependence on legitimately prescribed alprazolam and now needs a managed taper may or may not meet use-disorder criteria. The coder cannot decide that — the provider must document either the disorder (F13.2-) or its absence (Z79.899, with the taper managed under the anxiety or insomnia diagnosis being treated). Facilities running benzo-taper tracks should make this an explicit chart-review item, because payers notice when every taper admission arrives coded F13.20 with identical boilerplate.

The standard guidelines still apply on top: hierarchy per I.C.5.b.2 (use + abuse → abuse; anything + dependence → dependence), remission per I.C.5.b.1 (provider documentation only; mild → F13.11, moderate/severe → F13.21), and unspecified-use reportability per I.C.5.b.3.

Benzodiazepine withdrawal coding (F13.23x)

Sedative withdrawal is the clinical reason this family demands precision: untreated benzodiazepine withdrawal can progress to seizures and delirium, which is why F13 withdrawal codes — unlike opioid ones — carry the full 6th-character severity set:

Documentation that supports these codes and the detox claim built on them: the provider’s withdrawal diagnosis, the agent and last-use timing, serial withdrawal-severity assessments (CIWA-B-style instruments are common for benzodiazepines), seizure-risk factors, and the taper or substitution protocol ordered. SAMHSA ’s TIP 45 on detoxification ↗ outlines why sedative withdrawal generally warrants medical management rather than social detox — exactly the argument a medically monitored claim needs the chart to make. This page deliberately stays at the coding-and-documentation level; taper protocols are clinical decisions for the treating provider.

• F13.230 — withdrawal, uncomplicated
• F13.231 — withdrawal delirium: the dangerous end of the spectrum
• F13.232 — withdrawal with perceptual disturbance
• F13.239 — withdrawal, unspecified

Documentation requirements and chart shorthand

Per code group: a provider statement naming the agent class and pattern; explicit remission language for remission codes; documented withdrawal features for 6th-character specificity; and for induced disorders, the causal attribution in the provider’s words.

Billing and medical necessity

The polysubstance reality: F13 rarely travels alone. Alcohol-plus-benzodiazepine and opioid-plus-benzodiazepine presentations are common and clinically serious; each substance gets its own code — F13.2x alongside F10.2x or F11.2x. The hierarchy rule collapses stems only within one substance, never across substances. Multi-substance withdrawal documentation strengthens, not complicates, the medical-necessity case for monitored settings — see ASAM dimensions for how dimensional severity is framed, and denial codes in addiction treatment billing when the payer pushes back.

Treatment planning for sedative-related diagnoses

F13 treatment plans are taper-shaped: the medical objective (completing a supervised taper or substitution protocol) runs alongside the behavioral one (treating the anxiety or insomnia that started the prescription cascade). Plans should document both tracks against the diagnosis — and anticipate the step-down code change to F13.21 when the provider documents remission.

A fictional example: a 54-year-old with documented severe sedative use disorder (F13.20) enters medically monitored care for benzodiazepine withdrawal (coded F13.230 during the withdrawal-management phase); the plan pairs a physician-managed taper with twice-weekly therapy targeting rebound anxiety ( 90834 ); at discharge to IOP the diagnosis returns to F13.20, with remission documentation revisited at each plan review.

Structure and goal frameworks in our treatment plan guide.

More ICD-10 resources

Codes verified against the FY2026 ICD-10-CM tabular list (effective October 1, 2025). Reviewed against each annual ICD-10-CM update.

Detox documentation, taper tracking, and the claim that pays for both: ’s EHR and RCM were built for SUD facilities — request a demo.

Reference tables

Common questions

Official sources

• CDC/NCHScdc.gov
• CMScms.gov
• ICD-10-CM Official Guidelines FY2026ftp.cdc.gov
• TIP 45 on detoxificationncbi.nlm.nih.gov